Skip to main content

Client News

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

9th January 2026

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

8th January 2026

Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

8th January 2026

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

8th January 2026

AFYREN confirms drawdown of €7 million in previously secured financing for its subsidiary AFYREN NEOXY

8th January 2026

Abivax Provides 2026 Corporate Outlook

7th January 2026

Andera Partners Leads $67 Million Series A Financing in Spiro Medical to Develop a Neuromodulation System for Asthma

7th January 2026

AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15

7th January 2026

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan

7th January 2026

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

6th January 2026